ipl-logo

Epipens Case Summary

498 Words2 Pages

Legal rules currently do not sufficiently discourage predatory pricing of prescription drugs, in this case EpiPens. The price of EpiPens rising in the pharmaceutical industry is legal and immoral. However, Mylan Pharmaceuticals may have violated the antitrust law in its EpiPen sales to schools. In 1890 the United States passed down the antitrust law also known as the Sherman Act. The Sherman Act regulates the conduct and organization of business corporations in order to promote fair competition and outlaw monopolistic business practices. The Federal Trade Commissions Act was passed down in 1914, and it bans unfair methods of competition and unfair or deceptive acts or practices.. In August of 2012, Mylan Pharmaceuticals started the “EpiPen4Schools’ …show more content…

The complaint stated, “Defendant has a legal duty and obligation to set a fair, affordable, and reasonable [price] and not hold consumers hostage by forcing them to pay exorbitant prices for its medically necessary product”. Another lawsuit was filed in August in the federal court of Michigan for selling EpiPens in the US only in packs of two. The complaint stated, “Defendants have misstated the science regarding, and regulatory framework governing EpiPens in order to require consumers to buy extra, unneeded EpiPens, which are likely to go to waste, at an inflated cost.” In both lawsuits, the Plaintiffs have good reasons to file a lawsuit against Mylan. The Mylan Pharmaceutical company has been accused for many accusations but consumers have other alternative solutions if the company does not lower the price. An alternative solution for consumers who are uninsured is to apply to the Rx Advocacy program, which is a prescription assistance program to help those who are on high cost drugs but cannot afford them, regardless of their income level or qualifying for insurance. For

Open Document